TICKERNERD
Menu
AEONAEONHealthcare · Biotechnology

AEON Stock Forecast: AEON Biopharma, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$0.31

The 4 Wall Street analysts covering AEON Biopharma, Inc. hold a median 12-month price target of $2 — +542.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 7 Oct 2026 — in the upper half.

Market cap
$15.5M
Ticker Nerd rank
52 / 100
Median analyst target
$2.00
Analysts covering
4
Revenue$0.0
Operating income−$5.9M
Net income−$1.2M
Free cash flow−$3.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

AEON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AEON Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
99
Size
89
Revisions
60
Issuance
60
Volatility
48
Growth
41
Momentum
35
Value
23
Quality
12

Accruals (99): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AEON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AEON, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $1.20Median $2.00High $2.10

The green dot is the last close — the median target sits +542.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Oct 2026Lake StreetMaintainsBuy—
14 Aug 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026Lake StreetInitiatesBuy—
8 Oct 2025Aegis CapitalReiteratesBuy—
1 Oct 2024HC Wainwright & Co.ReiteratesBuy—
14 Aug 2024HC Wainwright & Co.MaintainsBuy—
10 July 2024HC Wainwright & Co.ReiteratesBuy—
30 May 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024HC Wainwright & Co.MaintainsBuy—
6 May 2024HC Wainwright & Co.ReiteratesBuy—
17 Apr 2024HC Wainwright & Co.ReiteratesBuy—
18 Aug 2023HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AEON appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AEON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

AEON Biopharma, Inc. (AEON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.3×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
−1.0×

Cheaper than 95% of US stocks

EV / EBITDA
−0.7×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
71.3%

Higher than 95% of US stocks

Return on assets
−141.5%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

AEON Biopharma, Inc. (AEON) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • AEON Biopharma, Inc. has a market value of $15.5M and an enterprise value of $13.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$54.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$13.6M.

  • Shares outstanding: 26.3M.

  • Trailing P/E: 0.3×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • AEON Biopharma, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

AEON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AEONAEON Biopharma, Inc.$15.5M
52
DAREDaré Bioscience, Inc.$15.3M
31
ALLRAllarity Therapeutics, Inc.$15.8M
30
PTNPalatin Technologies, Inc.$16.2M
38
NCELNewCelX Ltd.$16.2M
4
BCDABioCardia, Inc.$16.2M
41
KTTAPasithea Therapeutics Corp.$14.8M
15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AEON Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AEON news & analysis

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

GlobeNewsWire · 30 Sept 2026positive

AEON Biopharma received official minutes from its FDA Biosimilar Product Development Type 2b meeting for ABP-450, a proposed biosimilar to BOTOX. The FDA indicated that previously completed head-to-head studies versus BOTOX may be submitted as supportive evidence, with AEON expecting to advance the required bridging work and to submit an IND for a CMAP pharmacodynamic study in the fourth quarter of 2026.

Why it matters — The FDA feedback clarifies and potentially streamlines ABP-450's development path, giving AEON watchers greater visibility into the regulatory roadmap toward full-label U.S. market entry.

AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®

GlobeNewsWire · 9 Sept 2026positive

AEON Biopharma announced positive results from a pilot forced degradation study comparing ABP-450 to BOTOX under thermal and oxidative stress conditions. The results showed comparable rates of potency loss and similar site-specific oxidation patterns, providing additional analytical evidence supporting comparability and establishing the basis for AEON's planned multi-lot comparability study.

Why it matters — The results provide additional analytical evidence supporting ABP-450's comparability to BOTOX and lay the groundwork for AEON's planned multi-lot comparability study, marking progress in its biosimilar development program.

AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference

GlobeNewsWire · 31 Aug 2026neutral

AEON Biopharma announced that its management will host in-person 1x1 investor meetings at Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference in New York City on September 10, 2026. The announcement was made on August 31, 2026.

Why it matters — AEON watchers would care because the investor meetings provide an opportunity for the company to engage directly with investors at a prominent industry conference.

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

GlobeNewsWire · 24 Aug 2026positive

AEON Biopharma has designated Paul Lee, M.D., Ph.D., a former Deputy Director of the FDA's Office of Neuroscience, as its Acting Chief Regulatory Officer. Dr. Lee previously advised the company on regulatory strategy for its biosimilar candidate ABP-450 through Clintrex Research LLC.

Why it matters — Adding a former FDA neuroscience leader as Acting Chief Regulatory Officer could strengthen AEON's regulatory approach as it seeks full-label U.S. market entry for ABP-450.

AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®

GlobeNewsWire · 19 Aug 2026positive

AEON Biopharma reported expanded structural data supporting the molecular similarity of its candidate ABP-450 to BOTOX. Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed.

Why it matters — AEON watchers would care because the expanded structural evidence strengthens the case for ABP-450's molecular similarity to BOTOX, a key factor in the product's development and regulatory positioning.

FAQ

Frequently asked questions about AEON stock

What is the AEON stock price forecast for 2026-2027?

The 4 Wall Street analysts covering AEON Biopharma, Inc. have a median 12-month price target of $2, with estimates ranging from $1.2 to $2.1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AEON stock a buy right now?

Of the 4 analysts covering AEON Biopharma, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AEON Biopharma, Inc. 52 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AEON?

As at 7 Oct 2026, AEON Biopharma, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (99 of 100).

Will AEON stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +542.5% from the last close, and Ticker Nerd's factor model ranks AEON Biopharma, Inc. 52 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AEON stock forecast for 2030?

No analyst covering AEON Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AEON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $2.1 over the next 12 months.

What does AEON Biopharma, Inc. do?

Aeon Biopharma, Inc. Class A Common Stock represents the equity of Aeon Biopharma, Inc., a biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic use.

What is the latest news on AEON?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450". AEON Biopharma received official minutes from its FDA Biosimilar Product Development Type 2b meeting for ABP-450, a proposed biosimilar to BOTOX. The FDA indicated that previously completed head-to-head studies versus BOTOX may be submitted as supportive evidence, with AEON expecting to advance the required bridging work and to submit an IND for a CMAP pharmacodynamic study in the fourth quarter of 2026.

Company

About AEON Biopharma, Inc.

Aeon Biopharma, Inc. Class A Common Stock represents the equity of Aeon Biopharma, Inc., a biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic use. The company’s current work centers on ABP-450 (prabotulinumtoxinA), a botulinum toxin product candidate being studied for medical conditions such as cervical dystonia and migraine. Its business is concentrated on advancing injectable treatments for debilitating disorders and building a portfolio around toxin-based therapeutics. Aeon Biopharma operates in the healthcare and biotechnology sectors, where it plays the role of a specialized clinical-stage developer working to expand treatment options in neurology and related therapeutic areas. Based in Irvine, California, the company’s Class A common stock provides public market exposure to its ongoing research, development, and commercialization efforts in the biopharmaceutical market.

CEO Mr. Robert Bancroft · 8 employees · United States · https://www.aeonbiopharma.com